NEW DATE: 4th AMR Conference 2020 | Novel Antimicrobials & AMR Diagnostics
The 4th AMR Conference 2020 is a two-day conference that will bring together more than 400 international attendees active in the field of Antimicrobial Resistance (AMR), offering a platform for SMEs, industry, investors, clinicians, and regulatory experts to discuss the most urgent challenges with regard to R&D, clinical development, financing, and market access.
SMEs are facing specific challenges
Small and medium-sized enterprises (SMEs) provide more than 80 per cent of the approximately 400 antibacterial preclinical projects, identified in the first global antibacterial pipeline report, recently published by Ursula Theuretzbacher, Kevin Outterson, Aleks Engel, and Anders Karlén in Nature Reviews Microbiology. “After most large pharma companies have abandoned the field, SMEs drive the innovation and have adequate answers to win the fight with novel therapies overcoming antibiotic resistance. However, investment into the field must be reinvigorated by immediate action from policy, ensuring adequate pricing for life-saving and appropriately used drugs,” Marc Gitzinger, Vice President of the BEAM Alliance and CEO of Swiss BioVersys stressed. The developers’ industry association has published a position paper underlining the need to rapidly provide market-based solutions supporting SME-driven innovation against antimicrobial resistance.
100 speakers in 19 sessions
The 4th AMR Conference, which is supported by the BEAM Alliance and taking place for the first time in Basel, Switzerland, will take a close look into this challenge:
- Which new reimbursement models are currently underway?
- Which cross-national cooperation is needed and practicable to push forward fast solutions that particularly fulfil the needs of SMEs?
- Who is still investing in AMR, and which potentials offer global markets, such as India or China?
- Which business models are the most favourable for companies to survive the challenging market conditions?
- Which R&D trends and technologies are driving the pipeline towards novel antimicrobials and diagnostics?
Offering partnering, investors’ talks, and start-up pitches, financing will be a priority topic during the event. Speakers from the newly initiated EU-funded IMI AMR accelerator, the new impact investment fund supported by WHO and European Investment Bank, as well as AMR experts from stakeholders such as CARB-X, GARDP, Novo Holdings, and FDA, will provide their insights. Clinical treatment guidelines and a global perspective will be addressed in the program as well.
With a total of 100 high-level speakers in 19 sessions, the conference has a packed agenda of relevant topics in human and animal health, including sessions on tuberculosis, clinical trial networks, vaccines, novel therapeutic approaches, and ‘One Health’ strategies. Furthermore, a poster session, an exhibition, and a joint evening reception will invite conference participants to network. A Swiss pre-conference meeting and a pre-conference workshop organised by Novo REPAIR Impact Fund, CARB-X, GARDP and Wellcome Trust will be offered as well.
4th AMR Conference – Novel Antimicrobials & AMR Diagnostics
24–25 August 2020 | Congress Center Basel | Basel, Switzerland